| Single dose study in patients with chronic obstructive pulmonary disease (COPD) associated pulmonary hypertension. | |||
| Trial ID: | 12915 | ||
| This study is to demonstrate the safety, tolerability, pharmakokinetic and pharmacodynamic effect of a single oral dose of BAY 63-2521 in patients with pulmonary hypertension due to chronic obstructive pulmonary disease (COPD). | |||
| Indication/Disease: | Hypertension, Pulmonary Pulmonary Disease, Chronic Obstructive |
||
| Status: | Completed Trial Start Date:2008-08-22 |
||
| Phase: | Phase I/II | ||
| Trial Type: | Interventional Purpose:Treatment, Allocation: Non-randomized, Masking: Double Blind, Control: Uncontrolled, Assignment: Single Group Assignment, Number of arms:1, Number of participants: 23 |
||
| Trial Purpose: | Safety/Efficacy Study | ||
| Product: | Riociguat (BAY63-2521) | ||
| Intervention Type: | Drug | ||
| Sponsor: |
Bayer HealthCare AG |
||
| Countries: |
|
||
| Key Eligibility Criteria: |
Healthy Volunteers: No Gender :Both Minimum Age :18 Years Maximum Age :N/A Other inclusion / exclusion criteria may apply. |
||
| Primary outcomes: |
|
||
| Secondary outcomes: |
|
||
| Results/Links | |||
| This information is provided under Bayer Healthcare's for Publication of Clinical Trial Information. Please refer to the Read This First section. © 2006 Bayer HealthCare | |||
 Return to results
New search
Contact for this trial
|
|||
Search
Page tools
click to adjust font size
Social Bookmarks
Bayer HealthCare Links
Bayer scientific magazine
Clinical trials
Information about clinical studies is available at database of
Company Brochure
